Polar Capital Holdings Plc Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Polar Capital Holdings Plc grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 29.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 204,927 shares of the biopharmaceutical company’s stock after buying an additional 46,110 shares during the quarter. Polar Capital Holdings Plc’s holdings in Regeneron Pharmaceuticals were worth $158,177,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. WPG Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 25 shares during the period. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. Entrust Financial LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $32,000. Caitlin John LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Finally, MCF Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. Cantor Fitzgerald restated an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Finally, Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $900.00 to $700.00 in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Trading Down 0.0%

Shares of REGN stock opened at $614.73 on Wednesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $503.25 and a fifty-two week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock’s fifty day moving average is $686.23 and its two-hundred day moving average is $735.59. The firm has a market capitalization of $64.99 billion, a P/E ratio of 14.98, a PEG ratio of 1.35 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $8.22 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.